



MAGNASENSE ADVANCES SALIVA-BASED DIAGNOSTICS BREAKTHROUGH WITH PARTIALLY SECURED, ONGOING RIGHTS ISSUE – INVESTORS WELCOME TO PARTICIPATE UNTIL 8 MAY 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, JAPAN, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD NOT BE IN COMPLIANCE WITH APPLICABLE REGULATIONS OR WOULD REQUIRE REGISTRATION OR SIMILAR MEASURES. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE.

Rights Issue Open until 8 May 2025 – How and When to Subscribe

Magnasense AB ("Magnasense" or the "Company") invites existing and new shareholders to participate in its ongoing rights issue of units, aimed at strengthening working capital and advancing its innovative saliva-based disease diagnostics. The rights issue remains open for subscription until **8 May 2025**. Please note that certain banks and brokers may have an earlier deadline for submitting applications for subscriptions of units in the rights issue. Shareholders are therefore encouraged to check with their bank or broker to confirm whether an earlier deadline applies.

Account holders with Nordnet and Avanza can apply to subscribe for units, either with or without the support of preferential rights, via their respective online services until 7 May 2025 at 23:59. The last day to subscribe for units with and without preferential rights via Eminova Fondkommission is on Thursday 8 May 2025, at 15:00. More information about the subscription procedures via Nordnet, Avanza, and Eminova Fondkommission is available at www.nordnet.se, www.avanza.se and www.eminova.se.

- Subscribe via Nordnet [here](#).
- Subscribe via Avanza [here](#).
- Subscribe via Eminova Fondkommission [here](#).

The rights issue is subject to both a minimum and a maximum limit regarding the number of subscribed units. If fewer than 23,809,524 units are subscribed for with and without preferential rights in the rights issue, including units subscribed for within the framework of commitments, corresponding to approximately SEK 15 million or a subscription rate of approximately 56.2 per cent, the rights issue will not be carried out. As recently communicated, Magnasense has received **additional guarantee commitments totaling approximately SEK 8.8 million**,



securing the **minimum subscription level required for the completion of the rights issue ahead of it closing on 8 May 2025**. Including these additional commitments, subscription and guarantee commitments amount to a total of approximately SEK 15.4 million, corresponding to approximately 57.7 per cent of the rights issue.

The rights issue presents an opportunity for investors to support and take part in the development of a non-invasive, convenient, and cost-effective alternative to traditional blood testing. Shareholders who choose not to participate in the offering will experience dilution of their shareholding.

Why Invest Now?

Magnasense is developing saliva-based testing for diseases as an alternative to blood testing.

Magnasense is well advanced with its research and product development and is focusing its efforts on launching a **saliva-based diagnostic platform** to test for **Periodontitis**, a widespread and serious gum disease. This test is being developed for use by general practitioners, dentists, hygienists, and pharmacies, with a future vision to enable **at-home testing**, allowing individuals to monitor their own health.

The saliva-based approach opens the door to scalable diagnostics for a wide range of conditions including **diabetes, heart disease, and neurological disorders**, with strong future potential for AI-driven analysis of anonymised data to support tailored treatment recommendations.

Revenue will be driven by three channels:

- Licensing of the diagnostic technology
- Monetisation of anonymised health data
- Bespoke test result reporting services

Magnasense is executing disciplined **cost base optimization** through ongoing rationalization initiatives, building a **leaner, capital-efficient operation**. These actions strengthen **financial resilience** and provide **greater visibility into future capital requirements**—key drivers of **investor confidence and long-term value creation**.

Highlights for Investors

- **Minimum subscription level secured:** Ensures completion of the rights issue
- **High-growth market:** Non-invasive diagnostics are in global demand
- **Revenue-ready business model:** Targeting professional use first, with consumer rollout to follow
- **Clear path to scalability:** Through technology licensing and data monetisation



Magnasense believes its UK subsidiary, Aegirbio UK, is ideally positioned to commercialise these technologies and drive early, sustainable revenue. The proceeds from the rights issue will strengthen working capital and support the completion of the development of the saliva test system, enhance the cloud-based reporting platform, and progress partnership discussions with leading manufacturers and distributors.

For complete terms and conditions for the rights issue and other information about the Company, please refer to the information memorandum published by the Company on 22 April 2025, which is available at www.magnasense.com and www.eminova.se.

For media or investor enquiries, please contact:

Marco Witteveen, CEO

Email: ir@magnasense.com

The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

IMPORTANT INFORMATION

The publication, release or distribution of this press release in certain jurisdictions may be restricted by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”) and has not been approved or reviewed by any regulatory authority in any jurisdiction.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Canada, Australia, Hong Kong, New Zealand, South Africa, South Korea, Switzerland, Singapore, Japan, Russia, Belarus or any other



jurisdiction where such announcement, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

In the United Kingdom, this document, and any other materials in relation to the securities referred to herein, is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (**the "Order"**) or (ii) high net worth persons as referred to in Article 49(2)(a) to (d) of the Order (all such persons are collectively referred to as "relevant persons"). Any investment or investment activity to which this communication relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this press release and should not or act or rely on it.

This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in new shares. This press release does not constitute an invitation to underwrite, subscribe or otherwise acquire or transfer securities in any jurisdiction. This press release does not constitute a recommendation for any investor's decision regarding the Rights Issue. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities may go down as well as up and past performance is not a guide to future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does



not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the content of this press release, except as required by law or the rules of Nasdaq First North Growth Market.

About Magnasense

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.